ACADIA Pharmaceuticals Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Direxion Daily Semiconductor Bull 3X Shares trades at $142.08. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ACAD | SOXL | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.41 | $300.77 |
52-Week Low | $20.06 | $24.91 |
Enterprise Value | $4.19B | — |
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 13.02% to $146.92 amid renewed semiconductor sector optimism. The leveraged ETF remains in a technical bearish trend despite the recent rally, with moving averages signaling continued downward pressure. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the fund has experienced extreme volatility, dropping over 60% from its peak earlier this year before this rebound.
The outlook remains volatile with leveraged exposure amplifying both gains and losses. Investment opportunity exists for aggressive investors betting on sustained semiconductor recovery and AI infrastructure spending, but risks include extreme volatility decay, sector concentration, and macroeconomic sensitivity. The current technical setup suggests cautious entry near support levels may offer better risk-reward positioning.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →